Investigating Potential Cardiovascular Toxicity of Two Anti-Leukemia Drugs of Asciminib and Ponatinib in Zebrafish Embryos

BCR-ABL, a fusion protein kinase, is a druggable target exclusively expressed in patients with chronic myeloid leukemia (CML). Several anti-leukemia medicines targeting this protein have been developed in recent years. However, therapeutic options are limited for CML patients bearing multiple BCR-AB...

Descripción completa

Detalles Bibliográficos
Autores principales: Lin, Huan-Chau, Saputra, Ferry, Audira, Gilbert, Lai, Yu-Heng, Roldan, Marri Jmelou M., Alos, Honeymae C., Aventurado, Charlaine A., Vasquez, Ross D., Tsai, Guan-Jhe, Lim, Ken-Hong, Hsiao, Chung-Der
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9570146/
https://www.ncbi.nlm.nih.gov/pubmed/36233014
http://dx.doi.org/10.3390/ijms231911711

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9570146/
https://www.ncbi.nlm.nih.gov/pubmed/36233014
http://dx.doi.org/10.3390/ijms231911711

Ejemplares similares